MXPA06000675A - Derivado de quinolona o sal del mismo. - Google Patents

Derivado de quinolona o sal del mismo.

Info

Publication number
MXPA06000675A
MXPA06000675A MXPA06000675A MXPA06000675A MXPA06000675A MX PA06000675 A MXPA06000675 A MX PA06000675A MX PA06000675 A MXPA06000675 A MX PA06000675A MX PA06000675 A MXPA06000675 A MX PA06000675A MX PA06000675 A MXPA06000675 A MX PA06000675A
Authority
MX
Mexico
Prior art keywords
quinolone derivative
salt
pharmaceutically acceptable
acceptable salt
platelet aggregation
Prior art date
Application number
MXPA06000675A
Other languages
English (en)
Inventor
Takasakijun
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MXPA06000675A publication Critical patent/MXPA06000675A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems

Abstract

Se describe un inhibidor de agregacion de plaquetas que contiene un derivado de quinolona o una sal farmaceuticamente aceptable del mismo en la forma de un ingrediente activo; y un derivado de quinolona novedoso o una sal farmaceuticamente aceptable del mismo los cuales son utiles como inhibidores de agregacion de plaquetas.
MXPA06000675A 2003-07-24 2004-07-22 Derivado de quinolona o sal del mismo. MXPA06000675A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003278852 2003-07-24
PCT/JP2004/010781 WO2005009971A1 (ja) 2003-07-24 2004-07-22 キノロン誘導体又はその塩

Publications (1)

Publication Number Publication Date
MXPA06000675A true MXPA06000675A (es) 2006-04-19

Family

ID=34100788

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000675A MXPA06000675A (es) 2003-07-24 2004-07-22 Derivado de quinolona o sal del mismo.

Country Status (7)

Country Link
US (2) US7488739B2 (es)
EP (1) EP1650192A4 (es)
KR (1) KR20060041254A (es)
CN (1) CN100471842C (es)
CA (1) CA2530352A1 (es)
MX (1) MXPA06000675A (es)
WO (1) WO2005009971A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
KR20060041254A (ko) * 2003-07-24 2006-05-11 아스텔라스세이야쿠 가부시키가이샤 퀴놀론 유도체 또는 그의 염
US7495103B2 (en) 2004-06-24 2009-02-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
JP2008094720A (ja) * 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
GB0519758D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
DE602006015851D1 (de) * 2005-12-05 2010-09-09 Merck Sharp & Dohme Positive allosterische chinolon-m1-rezeptormodulatoren
US20090105272A1 (en) * 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
PT1993360T (pt) 2005-12-28 2017-05-25 Vertex Pharma Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
AU2007221207A1 (en) 2006-02-28 2007-09-07 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
PT2383271E (pt) * 2006-03-13 2013-10-10 Kyorin Seiyaku Kk Aminoquinolonas como inibidores de gsk-3
TWI391378B (zh) * 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
JP2010037198A (ja) * 2006-11-22 2010-02-18 Astellas Pharma Inc キノロン誘導体又はその製薬学的に許容される塩
WO2008131134A1 (en) * 2007-04-17 2008-10-30 Cylene Pharmaceuticals, Inc. Hydrazide compounds and uses thereof
US20100113391A1 (en) 2007-04-19 2010-05-06 Astellas Pharma Inc. Bicyclic heterocyclic compound
WO2008128647A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
AU2008266515B2 (en) 2007-06-18 2014-05-01 Sanofi Pyrrole derivatives as P2Y12 antagonists
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2692153A1 (en) 2007-06-27 2009-01-08 Richard W. Heidebrecht, Jr. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
US8389514B2 (en) 2007-09-11 2013-03-05 Kyorin Pharmaceutical Co., Ltd. Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
CN101855229A (zh) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 作为gsk-3抑制剂的螺环状氨基喹诺酮
BRPI0819696B1 (pt) * 2007-11-29 2018-10-23 Actelion Pharmaceuticals Ltd compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
US8071591B2 (en) 2009-03-11 2011-12-06 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as GSK-3 inhibitors
NZ624460A (en) 2009-03-20 2015-12-24 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8134020B2 (en) * 2009-12-10 2012-03-13 The United States Of America As Represented By The Secretary Of The Army Polymerization of hydroxytyrosol mediated by horseradish peroxidases
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
WO2012174013A2 (en) * 2011-06-14 2012-12-20 Cardeus Pharmaceuticals, Inc. Treatment of cardiovascular disease, stroke, and inflammatory conditions
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
EP3221295B1 (en) * 2014-11-17 2021-04-14 Nirogy Therapeutics, Inc. Monocarboxylate transport modulators and uses thereof
US9382208B1 (en) 2015-01-26 2016-07-05 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
CA2988468A1 (en) * 2015-06-09 2016-12-15 Bayer Pharma Aktiengesellschaft A 7-substituted-1-aryl-naphthyridin-3-carboxylic acid amide and its use as a positive allosteric modulator of the muscarinic m2 receptor
WO2018011017A1 (de) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung
EP3296298A1 (de) 2016-09-14 2018-03-21 Bayer Pharma Aktiengesellschaft 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
JOP20190045A1 (ar) * 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
WO2021181360A1 (en) * 2020-03-13 2021-09-16 Cadila Healthcare Limited Novel salts of quinolone compounds
GB202015056D0 (en) 2020-09-23 2020-11-04 Cambridge Entpr Ltd Biomarkers
WO2022195525A1 (en) * 2021-03-19 2022-09-22 Zydus Lifesciences Limited A quinolone compound in solid forms and processes for the preparation thereof
CN113461612B (zh) * 2021-07-20 2022-10-14 上海应用技术大学 一种喹诺酮类端锚聚合酶2抑制剂及其制备方法和应用
WO2023170724A1 (en) * 2022-03-08 2023-09-14 The University Of Jordan Use of substituted quinolone derivatives for treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433774A (en) 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
GB1444369A (en) * 1973-04-05 1976-07-28 Allen & Hanburys Ltd 1,8-naphthyridines
US4024255A (en) 1973-04-05 1977-05-17 Allen & Hanburys Limited Tetrazole containing naphthyridine-3-carboxamides
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
JPH08504194A (ja) * 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
TW301607B (es) * 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
ES2211965T3 (es) * 1995-08-02 2004-07-16 Darwin Discovery Limited Quinolonas y su utilizacion terapeutica.
DE69628019T2 (de) 1995-08-02 2004-01-22 Darwin Discovery Ltd., Slough Chinolone und deren therapeutische verwendung
DE69736812T2 (de) * 1996-11-27 2007-08-09 Bristol-Myers Squibb Pharma Co. Neue integrin rezeptor antagonisten
CA2271136C (en) * 1996-11-28 2008-11-25 Wakunaga Pharmaceutical Co., Ltd. Novel pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient
BR9814323A (pt) 1997-12-22 2004-06-29 Upjohn Co 4-hidroxiquinolina-3-carboxamidas e hidrazidas como agentes antiviróticos
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
TW500724B (en) 1999-10-05 2002-09-01 Pharmacia & Amp Upjohn Company Oxazinoquinolones useful for the treatment of viral infections
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DE60114994T2 (de) * 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco Blutplättchen-adp-rezeptor-inhibitoren
US6458788B1 (en) * 2000-03-21 2002-10-01 Pharmacia & Upjohn Company 4-hydroxycinnoline-3-carboxyamides as antiviral agents
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
GB2372986A (en) 2001-01-17 2002-09-11 Xenova Ltd 2-oxo, 4-hydroxy pyrroles and quinolines
WO2002070487A1 (en) 2001-03-01 2002-09-12 Pharmacia & Upjohn Company Substituted quinolinecarboxamides as antiviral agents
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
WO2003022214A2 (en) * 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
AU2003262947A1 (en) * 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
KR20060041254A (ko) * 2003-07-24 2006-05-11 아스텔라스세이야쿠 가부시키가이샤 퀴놀론 유도체 또는 그의 염

Also Published As

Publication number Publication date
US7488739B2 (en) 2009-02-10
CN1826321A (zh) 2006-08-30
WO2005009971A1 (ja) 2005-02-03
US20090124617A1 (en) 2009-05-14
KR20060041254A (ko) 2006-05-11
CN100471842C (zh) 2009-03-25
US7879878B2 (en) 2011-02-01
EP1650192A1 (en) 2006-04-26
EP1650192A4 (en) 2007-03-21
CA2530352A1 (en) 2005-02-03
US20060148806A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
MXPA06000675A (es) Derivado de quinolona o sal del mismo.
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
AU2003255845A1 (en) Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2004037176A3 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
AU2003248872A1 (en) Hiv integrase inhibitors
IL152916A0 (en) Heteroaryl-phenyl heterobicyclic factor xa inhibitors
IL175953A (en) Derivatives of 3-Cycloalkylaminopyrrolidine, their Pharmaceutical Salts and Preparations Containing Them
IL175512A0 (en) Methods of preparing aripiprazole crystalline forms
MXPA06000013A (es) Agente terapeutico para sarcoma de tejido suave.
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
EA200801199A1 (ru) Ингибиторы киназы
EP1704856A4 (en) PROTEIN INHIBITOR OF THE HSP90 FAMILY
CY1110664T1 (el) Ενδορινικες συνθεσετς
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
MXPA05010521A (es) Inhibidores de cinasa de amida de bifenilcarboxilica p38.
AP2005003451A0 (en) HIV integrase inhibitors.
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
TW200733963A (en) Cough inhibitor
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
ATE537822T1 (de) Antidepressivum
WO2005065047A3 (en) Stable oral composition containing desloratadine

Legal Events

Date Code Title Description
FG Grant or registration